Who is at risk
Most people with lymphoma have no identifiable risk factor at all. Nothing you did caused this. That said, the recognised associations are:
- Age — non-Hodgkin lymphoma is most often diagnosed between 65 and 74; Hodgkin lymphoma has a peak in young adults.
- A suppressed immune system — HIV, anti-rejection drugs after transplant, or long-term immunosuppressive therapy.
- Autoimmune disease — rheumatoid arthritis, Sjögren's, coeliac disease and Hashimoto's thyroiditis all carry a modestly raised risk.
- Certain infections — Epstein-Barr virus, H. pylori (gastric MALT lymphoma, which can sometimes be cured with antibiotics alone), hepatitis C, HTLV-1.
- Family history of lymphoma, and some chemical or radiation exposures.
Lymphoma is not contagious and is not caused by stress, diet or mobile phones.
Finding it early
There is no screening test for lymphoma. It is found because someone notices something and acts.
The classic sign is a painless swollen lymph node — in the neck, armpit or groin — that does not go away. Most swollen nodes are infection and settle within a few weeks. A node that is painless, rubbery, steadily enlarging, or still present after 4–6 weeks should be examined.
The "B symptoms" are specific and important, because they change the stage: unexplained fevers, drenching night sweats (soaking the sheets, not just feeling warm), and unintentional weight loss of more than 10% over six months. Persistent itching without a rash and fatigue are also recognised.
Nodes deep in the chest or abdomen can cause a cough, breathlessness, fullness after small meals, or back pain instead.
How it’s diagnosed
Lymphoma requires a proper biopsy — ideally the whole node removed (excisional biopsy) rather than a needle sample. The architecture of the node matters as much as the cells in it, and a fine needle often cannot classify lymphoma reliably. If you have been told a needle sample was "non-diagnostic," that is common and usually means a larger biopsy is needed, not that nothing is wrong.
Staging uses PET/CT, blood tests including LDH, and often a bone marrow biopsy. There are more than 60 subtypes of non-Hodgkin lymphoma, and the pathology report — not the stage — drives most of the treatment decision.
Ask two questions: what exact subtype is it, and is it indolent (slow-growing) or aggressive (fast-growing)? The answers point in opposite directions, and counterintuitively the aggressive ones are often the curable ones.
Staging explained simply
Lymphoma does not use the TNM system. It uses Ann Arbor staging, built around the diaphragm. A letter is added: A for no B symptoms, B if fevers, night sweats or weight loss are present.
Stage means something different here. In most cancers stage IV signals a poor outlook. In lymphoma, which travels through a system that already runs everywhere in the body, stage IV disease is frequently still treated with cure as the goal — and often achieved.
| Ann Arbor stage | What it means in plain words |
|---|---|
| Stage I | One lymph node region, or one organ site. |
| Stage II | Two or more node regions on the same side of the diaphragm — the breathing muscle that divides chest from abdomen. |
| Stage III | Node regions on both sides of the diaphragm. |
| Stage IV | Widespread involvement of organs outside the lymph system — bone marrow, liver, lung. |
Grading and biology
For lymphoma, the equivalent of grade is pace: indolent or aggressive.
Indolent lymphomas (follicular, marginal zone, CLL/SLL) grow slowly and may need no treatment for years — a strategy called watchful waiting. They are very treatable but often not curable, behaving more like a chronic condition.
Aggressive lymphomas (diffuse large B-cell, Burkitt) grow quickly and need treatment promptly — and are frequently cured. Being told your lymphoma is aggressive is frightening and is often better news than the alternative.
Prognostic scores (IPI for large B-cell, FLIPI for follicular) combine age, stage, LDH, performance status and sites involved. Cell-of-origin and genetic features such as MYC, BCL2 and BCL6 rearrangements refine treatment further.
How it’s treated
Chemo-immunotherapy is the backbone. Adding the antibody rituximab to chemotherapy transformed B-cell lymphoma outcomes, and the survival improvements visible in the SEER data from the late 1990s onward largely reflect that.
Watchful waiting is a legitimate, evidence-based plan for asymptomatic indolent lymphoma. Treating earlier does not help, and it spends side effects you may not need for years. It is hard to accept and it is not neglect.
Radiation has a real and specific role here. Lymphoma is one of the most radiosensitive cancers there is. Early-stage Hodgkin and some early-stage non-Hodgkin lymphomas are treated with short chemotherapy plus modest-dose involved-site radiation. Very low doses — sometimes just two treatments — can control indolent lymphoma or relieve symptoms remarkably well. Modern involved-site technique treats far less tissue than the wide fields used decades ago, which matters greatly for long-term risk.
CAR T-cell therapy and bispecific antibodies have changed the outlook for relapsed aggressive lymphoma, sometimes producing durable remissions after everything else has failed.
Where CureRays fits: we are radiation specialists, and lymphoma is a disease where radiation genuinely earns its place — often at lower doses and smaller fields than people expect.
What the guidelines say
In broad strokes: obtain an adequate biopsy and an exact subtype before treating; stage with PET/CT; for indolent asymptomatic disease consider observation; treat aggressive B-cell lymphoma with chemo-immunotherapy aiming at cure; use involved-site radiation for early-stage disease and for consolidation or symptom control; and consider CAR T-cell therapy or bispecific antibodies at relapse.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Figures are for non-Hodgkin lymphoma. Source: NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma, SEER 17, 2014–2020, by Ann Arbor stage. Overall 5-year relative survival is 74.3%.
| Ann Arbor stage at diagnosis | Share of cases | 5-year relative survival |
|---|---|---|
| Stage I — one region | 22% | 87.0% |
| Stage II — multiple regions, one side of the diaphragm | 15% | 78.9% |
| Stage III — both sides of the diaphragm | 18% | 73.6% |
| Stage IV — widespread | 36% | 64.2% |
| Unstaged | 9% | 71.6% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
Hodgkin lymphoma is reported separately by SEER and is among the most curable of all cancers, including at advanced stage. We have not quoted a Hodgkin figure here because the SEER page we could retrieve was an outdated snapshot, and we would rather give you no number than a stale one — see SEER Stat Facts: Hodgkin Lymphoma for current figures, and ask your team for numbers matched to your subtype and risk score.
Note the trend: non-Hodgkin lymphoma death rates have been falling about 2.1% a year (SEER, 2013–2022), and 5-year survival rose from roughly 50% in the 1970s to about 74% today.
Side effects and how we watch for them
Chemo-immunotherapy: low blood counts and infection risk, fatigue, nausea, hair loss and neuropathy from vincristine. A fever during treatment is an emergency — neutropenic sepsis needs antibiotics within the hour, not a wait-and-see. Know your team's emergency number.
Radiation: effects depend on the site. Neck treatment can affect the thyroid and swallowing; chest treatment involves the heart, lungs and — importantly for young women — breast tissue. Because so many lymphoma patients are cured and young, long-term risk drives technique: involved-site fields, lower doses, breath-hold and proton therapy where appropriate all exist to reduce second cancers and heart disease decades later.
CAR T-cell therapy has its own distinct risks — cytokine release syndrome and neurological effects — managed in specialist centres.
How it is assessed: graded on a standard scale each visit, with blood counts, and thyroid and cardiac surveillance for those who had neck or chest radiation.
Follow-up, remission and survivorship
Complete remission means no detectable lymphoma on PET/CT. For aggressive lymphoma treated successfully, that is usually the end of the story — most relapses occur within the first two years, and passing that mark is meaningful. For indolent lymphoma, remission and relapse may alternate over decades.
Follow-up is mostly clinical examination and blood tests every few months at first, then annually. Routine surveillance scanning is used less than it once was, because most relapses are found by symptoms or examination rather than by scans.
Survivorship after lymphoma deserves real attention, because so many survivors are young: thyroid function after neck radiation, cardiovascular risk after chest treatment, fertility (ask about preservation before treatment), vaccination, and screening for second cancers — including earlier breast screening for women treated to the chest at a young age. Ask for a written survivorship plan.
Questions people actually ask
My node has been there three weeks. Should I worry?
Probably not yet — most swollen nodes are reactive and settle within a few weeks. A painless, rubbery node that keeps growing, or one still present after 4–6 weeks, should be examined.
Stage IV sounds like the end. Is it?
Not in lymphoma. Because the lymph system runs throughout the body, widespread involvement is common at diagnosis and stage IV disease is still frequently treated with cure as the goal. Subtype matters more than stage here.
Why is my doctor not treating me?
For indolent lymphoma without symptoms, watchful waiting is evidence-based. Treating earlier has not been shown to help, and it uses up side effects you may not need for years. It should come with a clear monitoring schedule.
Is it better to have an aggressive or indolent lymphoma?
Counterintuitively, aggressive lymphomas are often the curable ones, while indolent ones are very treatable but tend to return. Neither answer is simply 'better' — they are different diseases with different plans.
Will radiation give me another cancer?
There is a small long-term increase in risk, which is precisely why modern practice uses involved-site fields, lower doses and techniques like breath-hold. The fields used in the 1980s were far larger than anything used today.
Informational only, not medical advice — confirm with your care team.
Go deeper on lymphoma
Read the full plain-language guide, or ask our team where radiation fits in your subtype.